Alpha 2.0
Login Register
» Authors » Andrew Mujugira

Andrew Mujugira

Explore the profile of Andrew Mujugira including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 112
Citations 3683
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Public Health
Top 10 Co-Authors
Connie Celum
Jared M Baeten
Renee Heffron
Timothy R Muwonge
Nelly Mugo
Norma C Ware
Monique A Wyatt
Jessica E Haberer
Agnes Nakyanzi
Deborah Donnell
Published In
J Acquir Immune Defic Syndr
J Int AIDS Soc
AIDS Behav
J Infect Dis
PLoS One
Affiliations
Soon will be listed here.
Recent Articles
1.
Barriers and facilitators of adherence to long-term antiretroviral treatment in Kampala, Uganda
Okoboi S, Mujugira A, Nekesa N, Castelnuovo B, Lippman S, King R
PLOS Glob Public Health . 2025 Mar; 5(3):e0004121. PMID: 40080505
Few qualitative studies have evaluated adherence to long-term antiretroviral treatment (ART) in sub-Saharan Africa. We explored adherence barriers and facilitators among PLWH on long-term ART (≥10 years in Kampala)., We...
2.
High prevalence of multidrug-resistant bacteria on patient medical file surfaces at five critical care units in Kampala, Uganda: an explanatory sequential mixed-methods study
Kyamulabi M, Izudi J, Mujugira A, Okoboi S
Infect Control Hosp Epidemiol . 2025 Feb; :1-3. PMID: 40012277
Introduction: Intensive care units (ICUs) and high-dependency units (HDUs) care for critically ill patients, many of whom have multi-drug-resistant (MDR) bacteria. We investigated the prevalence and distribution of MDR bacteria...
3.
POC Viral Load Testing in an Antenatal Clinic Setting for Ugandan Pregnant Women Living with HIV: An Implementation Process Analysis
Ware N, Wyatt M, Nakyanzi A, Naddunga F, Pisarski E, Kyomugisha J, et al.
Discov Health Syst . 2025 Feb; 3. PMID: 39896214
Introduction: Viral suppression during pregnancy and postpartum sustains the health of mothers living with HIV and reduces risk of transmitting HIV to newborns. Point of care viral load (POC VL)...
4.
HIV clinical outcomes among people with HIV and diabetes mellitus in Kampala, Uganda; A matched retrospective cohort study
Nakalega R, Semitala F, Mutebi E, Mawanda D, Lukyamuzi Z, Menge R, et al.
PLOS Glob Public Health . 2025 Jan; 5(1):e0003922. PMID: 39820139
Suppressive antiretroviral treatment (ART) has resulted into prolonged survival of people with HIV (PWH) in Sub-Saharan Africa (SSA) with resultant increase in the incidence of non-communicable diseases (NCD), such as...
5.
Impact of COVID-19 Public Health Measures on Antiretroviral Therapy Use Among Ugandans Living with HIV in Sero-Different Couples
Muwonge T, Feutz E, Nsubuga R, Simoni J, Nambi F, Nakabugo L, et al.
AIDS Behav . 2025 Jan; PMID: 39789392
Antiretroviral therapy (ART) use and HIV suppression among people living with HIV (PLHIV) are critical for HIV control and prevention. Extreme restrictions on movement early during the COVID-19 pandemic in...
6.
Bone density changes in young women in Uganda using tenofovir-based HIV preexposure prophylaxis and depot medroxyprogesterone acetate contraception
Heffron R, Muwonge T, Thomas K, Zewdie K, Ssebuliba T, Stein G, et al.
AIDS . 2024 Dec; 39(2):123-132. PMID: 39729557
Background: Injectable depot medroxyprogesterone acetate (DMPA) is the most common contraceptive choice among young women in Uganda, where HIV burden is high and HIV preexposure prophylaxis (PrEP) may be offered....
7.
Pre-HIV α4β7hi CD4+ T cells and HIV risk among heterosexual individuals in Africa
Omole T, Nguyen H, Marcinow A, Oo M, Jahan N, Ssemaganda A, et al.
J Infect Dis . 2024 Dec; PMID: 39720913
Background: CD4+ T cells expressing α4β7 are optimal targets for HIV infections, with higher pre-HIV α4β7hi expression linked to increased HIV acquisition and progression in South African women. However, similar...
8.
Alignment of PrEP Use With Potential HIV Exposure in Young Women and Men in Uganda
Wu L, Ssebuliba T, Muwonge T, Bambia F, Stein G, Nampewo O, et al.
J Acquir Immune Defic Syndr . 2024 Dec; 98(4):326-333. PMID: 39630076
Background: Despite high oral pre-exposure prophylaxis (PrEP) uptake among young heterosexual cisgender women, early discontinuation is frequent. It is unclear whether this aligns with potential HIV exposure. Methods: Young women...
9.
Peer-Delivered HIV Self-Testing, Sexually Transmitted Infection Self-Sampling, and Pre-exposure Prophylaxis for Transgender Women in Uganda: A Randomized Trial
Mujugira A, Karungi B, Nakyanzi A, Bagaya M, Nsubuga R, Sebuliba T, et al.
J Acquir Immune Defic Syndr . 2024 Sep; 97(2):125-132. PMID: 39250646
Background: Peer-delivered HIV self-testing (HIVST) and sexually transmitted infection self-sampling (STISS) may promote adherence to oral pre-exposure prophylaxis (PrEP), but no studies have analyzed this approach among transgender women (TGW)...
10.
Integrated PrEP and STI Services for Transgender Women in Uganda: Qualitative Findings from a Randomized Trial
Mujugira A, Nakyanzi A, Bagaya M, Mugisha J, Kamusiime B, Nalumansi A, et al.
AIDS Behav . 2024 Sep; 29(1):133-142. PMID: 39222182
Tenofovir alafenamide fumarate (F/TAF) pre-exposure prophylaxis (PrEP) is understudied in sub-Saharan Africa. The Tandika PrEP study was a randomized trial that evaluated same-day F/TAF initiation, the impact of drug-level feedback...